Akorn Net debt/EBITDA
Mi az Akorn Net debt/EBITDA?
A Net debt/EBITDA az Akorn, Inc. - 128.44
Mi a Net debt/EBITDA meghatározása?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA a Health Care szektor a OTC-on cégekben a Akorn -hoz képest
Mit csinál Akorn?
Akorn, Inc., a specialty pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Further, the company sells its products to wholesale distributors. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois. On May 20, 2020, Akorn, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
net debt/ebitda -hoz hasonló cégek Akorn
- Stuart Olson nak Net debt/EBITDA 126.30 van
- Wang On nak Net debt/EBITDA 126.48 van
- ALBIS Leasing AG nak Net debt/EBITDA 126.62 van
- Charah Solutions Inc nak Net debt/EBITDA 126.71 van
- Fuel Tech Inc nak Net debt/EBITDA 127.16 van
- D&G Technology nak Net debt/EBITDA 127.56 van
- Akorn nak Net debt/EBITDA 128.44 van
- Clipper Realty Inc nak Net debt/EBITDA 128.52 van
- America Movil S.A.B.DE C.V nak Net debt/EBITDA 128.66 van
- Waterstone Inc nak Net debt/EBITDA 128.70 van
- Liberty Media nak Net debt/EBITDA 129.25 van
- Feiyang International nak Net debt/EBITDA 130.36 van
- Syndax Pharmaceuticals Inc nak Net debt/EBITDA 130.74 van